These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2142236)

  • 1. Effect of toremifene on clinical chemistry, hematology and hormone levels at different doses in healthy postmenopausal volunteers: phase I study.
    Kivinen S; Mäenpää J
    J Steroid Biochem; 1990 Jun; 36(3):217-20. PubMed ID: 2142236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hormonal effects of toremifene in breast cancer patients.
    Számel I; Vincze B; Hindy I; Kerpel-Fronius S; Eckhardt S; Mäenpää J; Grönroos M; Kangas L; Sundquist H; Hajba A
    J Steroid Biochem; 1990 Jun; 36(3):243-7. PubMed ID: 2142246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of toremifene on estrogen primed vaginal mucosa in postmenopausal women.
    Mäenpää J; Söderström KO; Grönroos M; Taina E; Hajba A; Kangas L
    J Steroid Biochem; 1990 Jun; 36(3):221-3. PubMed ID: 2142237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogenic effects of toremifene and tamoxifen in postmenopausal breast cancer patients.
    Ellmén J; Hakulinen P; Partanen A; Hayes DF
    Breast Cancer Res Treat; 2003 Nov; 82(2):103-11. PubMed ID: 14692654
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-dependent hormonal effects of toremifene in postmenopausal breast cancer patients.
    Ellmén J; Werner D; Hakulinen P; Keiling R; Fargeot P; Falkson G; Bezwoda WR
    Cancer Chemother Pharmacol; 2000; 45(5):402-8. PubMed ID: 10803924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of low dose oestrogen on circulating prolactin. LH and FSH levels in post-menopausal women.
    Robyn C; Vekemans M
    Acta Endocrinol (Copenh); 1976 Sep; 83(1):9-14. PubMed ID: 989226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study.
    Valavaara R; Pyrhönen S; Heikkinen M; Rissanen P; Blanco G; Thölix E; Nordman E; Taskinen P; Holsti L; Hajba A
    Eur J Cancer Clin Oncol; 1988 Apr; 24(4):785-90. PubMed ID: 2968265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a new LH-RH analogue (D-Ser(TBU)6-EA10-LH-RH) on gonadotrophin and gonadal steroid secretion in men.
    Wiegelmann W; Solbach HG; Kley HK; Nieschlag E; Rudorff KH; Krüskemper HL
    Horm Res; 1976; 7(1):1-10. PubMed ID: 793974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of toremifene in breast cancer patients. Preliminary communication.
    Hindy I; Juhos E; Szántó J; Számel I
    J Steroid Biochem; 1990 Jun; 36(3):225-6. PubMed ID: 2142238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pituitary-ovarian relationships preceding the menopause. I. A cross-sectional study of serum follice-stimulating hormone, luteinizing hormone, prolactin, estradiol, and progesterone levels.
    Reyes FI; Winter JS; Faiman C
    Am J Obstet Gynecol; 1977 Nov; 129(5):557-64. PubMed ID: 910845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The anti-estrogenic effect of 4-chloro-1,2-diphenyl-1-(4-[2-(N,N-dimethylamino)ethoxy]phenyl)1-butene (Toremifene) on the endocrine regulation in breast cancer patients].
    Számel I; Hindy I; Vincze B; Ady N; Eckhardt S
    Orv Hetil; 1991 Mar; 132(13):683-6. PubMed ID: 1826556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the tolerance and pharmacokinetics of toremifene in patients with cancer.
    Kohler PC; Hamm JT; Wiebe VJ; DeGregorio MW; Shemano I; Tormey DC
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S19-26. PubMed ID: 2149280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the pharmacological properties of toremifene.
    Kangas L
    J Steroid Biochem; 1990 Jun; 36(3):191-5. PubMed ID: 2142231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placebo-controlled comparison of hormonal and biochemical effects of danazol and high-dose medroxyprogesterone acetate.
    Telimaa S; Apter D; Reinilä M; Rönnberg L; Kauppila A
    Eur J Obstet Gynecol Reprod Biol; 1990; 36(1-2):97-105. PubMed ID: 2142109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trials with toremifene in advanced breast cancer: a review.
    Valavaara R
    Breast Cancer Res Treat; 1990 Aug; 16 Suppl():S31-5. PubMed ID: 2149283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Droloxifene, a new antiestrogen. Hormonal influences in postmenopausal breast cancer patients.
    Kvinnsland S
    Am J Clin Oncol; 1991; 14 Suppl 2():S46-51. PubMed ID: 1962597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of toremifene in patients with advanced cancer.
    Hamm JT; Tormey DC; Kohler PC; Haller D; Green M; Shemano I
    J Clin Oncol; 1991 Nov; 9(11):2036-41. PubMed ID: 1834808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Endocrine effect of a new anti-estrogen compound (EGIS-5650, panomifene) in healthy volunteers: phase I/a study].
    Számel I; Budai B; Gyergyay F; Erdélyi-Tóth V; Kralovánsky J; Drabant S; Csörgö M; Zsarnóczay P
    Orv Hetil; 1994 May; 135(20):1077-81. PubMed ID: 7519764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of antiestrogen drugs on the sex hormone and sex hormone-binding globulin levels in breast cancer patients.
    Számel I; Hindy I; Vincze B; Kerpel-Fronius S; Eckhardt S
    Ann N Y Acad Sci; 1988; 538():265-79. PubMed ID: 2973277
    [No Abstract]   [Full Text] [Related]  

  • 20. Concordant suppression of serum immunoreactive luteinizing hormone (LH), follicle-stimulating hormone, alpha subunit, bioactive LH, and testosterone in postmenopausal women by a potent gonadotropin releasing hormone antagonist (detirelix).
    Andreyko JL; Monroe SE; Marshall LA; Fluker MR; Nerenberg CA; Jaffe RB
    J Clin Endocrinol Metab; 1992 Feb; 74(2):399-405. PubMed ID: 1370507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.